Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer

NANot yet recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

November 1, 2026

Study Completion Date

January 1, 2028

Conditions
Cytoreductive Surgery
Interventions
OTHER

cytoreductive surgery

Open surgery is conducted by senior doctors in gynecological oncology. The following parameters should be recorded: period of operation, location and number of recurrent lesions, location and number of resected lesions, amount of intraoperative bleeding and blood transfusion, whether R0 is reached, size and distribution of residual lesions, surgical complications, hospital stay, and period to adjuvant chemotherapy. Patients are required to start intravenous chemotherapy within 4W after surgery, at least for 4 cycles.

Trial Locations (2)

Unknown

Women's Hospital, Zhejiang University School of Medicine, Hangzhou

Women's Hospital, Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Women's Hospital School Of Medicine Zhejiang University

OTHER

NCT05633199 - Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancer | Biotech Hunter | Biotech Hunter